T cell coinhibition and immunotherapy in human breast cancer.

Murali Janakiram, Yael M. Abadi, Joseph A. Sparano, Xingxing Zang

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Costimulation and coinhibition generated by the B7 family and their receptor CD28 family have key roles in regulating T lymphocyte activation and tolerance. These pathways are very attractive therapeutic targets for human cancers including breast cancer. Gene polymorphisms of B7x (B7-H4/B7S1), PD-1 (CD279), and CTLA-4 (CD152) are associated with increased risk of developing breast cancer although the underlying mechanisms are unclear. In human breast cancer microenvironment, up-regulation of coinhibitory B7/CD28 members B7x, B7-H3 (CD276), and PD-L1 (B7-H1/CD274) on tumor cells as well as PD-1 and PD-L1 on tumor-infiltrating immune cells are emerging as immune evasion pathways. Chemotherapy can affect the expression of these molecules, and therefore may dampen the immune response against breast cancer. Immunotherapy targeting T cell coinhibition as monotherapy or combined with standard therapies are in early stages of clinical development, but hold great promise for treatment of human breast cancer.

Original languageEnglish (US)
Pages (from-to)229-236
Number of pages8
JournalDiscovery medicine
Volume14
Issue number77
StatePublished - Oct 2012

Fingerprint

Immunotherapy
Breast Neoplasms
T-Lymphocytes
Immune Evasion
Tumor Microenvironment
Lymphocyte Activation
Neoplasms
Up-Regulation
Therapeutics
Drug Therapy
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

T cell coinhibition and immunotherapy in human breast cancer. / Janakiram, Murali; Abadi, Yael M.; Sparano, Joseph A.; Zang, Xingxing.

In: Discovery medicine, Vol. 14, No. 77, 10.2012, p. 229-236.

Research output: Contribution to journalArticle

Janakiram, Murali ; Abadi, Yael M. ; Sparano, Joseph A. ; Zang, Xingxing. / T cell coinhibition and immunotherapy in human breast cancer. In: Discovery medicine. 2012 ; Vol. 14, No. 77. pp. 229-236.
@article{8172cdeaf3c146e2991aeafc29c0ea44,
title = "T cell coinhibition and immunotherapy in human breast cancer.",
abstract = "Costimulation and coinhibition generated by the B7 family and their receptor CD28 family have key roles in regulating T lymphocyte activation and tolerance. These pathways are very attractive therapeutic targets for human cancers including breast cancer. Gene polymorphisms of B7x (B7-H4/B7S1), PD-1 (CD279), and CTLA-4 (CD152) are associated with increased risk of developing breast cancer although the underlying mechanisms are unclear. In human breast cancer microenvironment, up-regulation of coinhibitory B7/CD28 members B7x, B7-H3 (CD276), and PD-L1 (B7-H1/CD274) on tumor cells as well as PD-1 and PD-L1 on tumor-infiltrating immune cells are emerging as immune evasion pathways. Chemotherapy can affect the expression of these molecules, and therefore may dampen the immune response against breast cancer. Immunotherapy targeting T cell coinhibition as monotherapy or combined with standard therapies are in early stages of clinical development, but hold great promise for treatment of human breast cancer.",
author = "Murali Janakiram and Abadi, {Yael M.} and Sparano, {Joseph A.} and Xingxing Zang",
year = "2012",
month = "10",
language = "English (US)",
volume = "14",
pages = "229--236",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "77",

}

TY - JOUR

T1 - T cell coinhibition and immunotherapy in human breast cancer.

AU - Janakiram, Murali

AU - Abadi, Yael M.

AU - Sparano, Joseph A.

AU - Zang, Xingxing

PY - 2012/10

Y1 - 2012/10

N2 - Costimulation and coinhibition generated by the B7 family and their receptor CD28 family have key roles in regulating T lymphocyte activation and tolerance. These pathways are very attractive therapeutic targets for human cancers including breast cancer. Gene polymorphisms of B7x (B7-H4/B7S1), PD-1 (CD279), and CTLA-4 (CD152) are associated with increased risk of developing breast cancer although the underlying mechanisms are unclear. In human breast cancer microenvironment, up-regulation of coinhibitory B7/CD28 members B7x, B7-H3 (CD276), and PD-L1 (B7-H1/CD274) on tumor cells as well as PD-1 and PD-L1 on tumor-infiltrating immune cells are emerging as immune evasion pathways. Chemotherapy can affect the expression of these molecules, and therefore may dampen the immune response against breast cancer. Immunotherapy targeting T cell coinhibition as monotherapy or combined with standard therapies are in early stages of clinical development, but hold great promise for treatment of human breast cancer.

AB - Costimulation and coinhibition generated by the B7 family and their receptor CD28 family have key roles in regulating T lymphocyte activation and tolerance. These pathways are very attractive therapeutic targets for human cancers including breast cancer. Gene polymorphisms of B7x (B7-H4/B7S1), PD-1 (CD279), and CTLA-4 (CD152) are associated with increased risk of developing breast cancer although the underlying mechanisms are unclear. In human breast cancer microenvironment, up-regulation of coinhibitory B7/CD28 members B7x, B7-H3 (CD276), and PD-L1 (B7-H1/CD274) on tumor cells as well as PD-1 and PD-L1 on tumor-infiltrating immune cells are emerging as immune evasion pathways. Chemotherapy can affect the expression of these molecules, and therefore may dampen the immune response against breast cancer. Immunotherapy targeting T cell coinhibition as monotherapy or combined with standard therapies are in early stages of clinical development, but hold great promise for treatment of human breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84875963683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875963683&partnerID=8YFLogxK

M3 - Article

C2 - 23114578

AN - SCOPUS:84875963683

VL - 14

SP - 229

EP - 236

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 77

ER -